Randomized controlled trialHuman
Afamelanotide for Erythropoietic Protoporphyria
The New England journal of medicine, 2015 Jul 2. Langendonk JG, Balwani M, Anderson KE and 23 others.
Study type
Randomized controlled trial
Subjects
Human participants (PubMed MeSH: Humans)
Journal
The New England journal of medicine
Published
2015 Jul 2
PubMed
Where PepCue cites this
This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.
Indexed under
MeSH terms assigned by the National Library of Medicine.
AdultDouble-Blind MethodDrug ImplantsHumansMiddle AgedPainProtoporphyria, ErythropoieticSunlightalpha-MSH
Other papers on Afamelanotide
Review · 2019
Eruptive Melanocytic Nevi: A Review
Review · 2017Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders
Journal article · 2022Objective light exposure measurements and circadian rhythm in patients with erythropoietic protoporphyria: A case-control study
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page